NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
News|Articles|July 12, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-08-01-2018
- Volume 13
- Issue 8
Catalent Implements Optofluidic Platform for Cell-Line Development
Author(s)Pharmaceutical Technology Editors
Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.
Advertisement
Catalent Pharma Solutions and Berkeley Lights announced in a July 10, 2018 press release that Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.
The Beacon platform is capable of screening thousands of clones in parallel and identifying top-producing clones in five days. According to Catalent, automating the process on the platform provides additional insights into the behavior of clonal populations that are currently unavailable using traditional techniques.
The four integrated workflows of the platform-import, culture, assay, and export-will be applied to Catalent Biologics’ GPEx cell-line development platform as well as Catalent’s ongoing research and development activities.
Source:
Articles in this issue
about 8 years ago
Bioprocessing Sees Advances in Analytical Toolsabout 8 years ago
Benchtop Sample Preparation Stationabout 8 years ago
A-Alpha Bio Wins NSF Grant for Cancer Drug Developmentabout 8 years ago
Waters Acquires Mass Spec Technologyabout 8 years ago
Fully Integrated Karl Fischer Titratorabout 8 years ago
Almac to Invest in Analytical Services CapabilityAdvertisement
Related to this article
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Rare Disease Framework Puts CMC Review in Scope
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Using Automation to Enhance Manufacturing: Building the Foundation for Pharma 4.0
5